Q1 2020 Insulet Corp Earnings Call
Microsoft is helping to lead the Dow Jones Industrial Average to a bullish second quarter so far. These growth stocks are also breaking out.
PODD earnings call for the period ending March 31, 2020.
The Dow Jones Industrial Average is demonstrating resilience, erasing an early 2% loss, unfazed by news of another big surge in weekly jobless claims.
Dow Jones futures signal more gains in the post coronavirus stock market rally. Several stocks moved on earnings just after breaking out. Will Tesla Fremont open?
Insulet is the IBD Stock Of The Day as Wall Street calls for the diabetes treatment player to outmaneuver the coronavirus pandemic. PODD stock is currently forming a cup-with-handle base.
With all the attention that COVID-19-related companies have gotten over the past couple of months, it's easy to forget that there are plenty of other promising stocks out there to invest in. While there are other insulin pump makers on the market, such as Tandem Diabetes, Insulet's OmniPod stands out for a couple of reasons.
You can't follow all of this week's reports, but keep an eye on Shopify, PayPal, Apple supplier Lumentum and others near buy points with earnings due.
Futures were mixed Monday while Tesla fell as China sales dived and Elon Musk threatened to leave California, Microsoft and Netflix are near buy points in the stock market rally.
Insulet working on cup-with-handle base. Earnings due Thursday night. Break-even seen after two qtrs. of declining profit, but improving EPS in next 3 quarters.Insulet (PODD, daily) working on cup-with-handle base. Earnings due Thursday night. Break-even seen after two qtrs. of declining profit, but improving EPS in next 3 quarters. Dexcom and Tandem Diabetes reported last week
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at two upcoming investor conferences:
The diabetes stock initially traded lower on earnings, but it didn't take long for buyers to regain control.
Late Thursday, diabetes treatment company Insulet trimmed its 2020 outlook following a mixed first quarter — leading Insulet stock to dip in after-hours trading.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended March 31, 2020.
Shares of Insulet (NASDAQ: PODD), which makes the Omnipod tubeless insulin pump, surged 20.6% in April, according to data from S&P Global Market Intelligence. The S&P 500 index returned 12.8% last month. In 2020, shares of the fast-growing healthcare stock are up 13.8% through May 1, whereas the S&P 500 has returned negative 11.8% over this period.
Insulet (PODD) delivered earnings and revenue surprises of -50.00% and 4.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.
Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the pricing of its $500 million common stock registered underwritten offering at $211.00 per share, in which Insulet will sell 2,369,668 shares. Insulet granted the underwriters a 30-day option to purchase up to 355,450 additional shares to be sold directly by Insulet to the underwriters.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it plans to make an offering of $500 million of its common stock in a registered underwritten offering. Insulet expects to grant the underwriters a 30-day option to purchase up to $75 million of additional shares.